In accordance with advice from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) on Iopofosine I 131 for Waldenstrom's Macroglobulinemia (WM) treatment, a submission for Conditional Marketing Approval in Europe is anticipated in the third quarter of 2026.